Published in J Allergy Clin Immunol on December 26, 2007
The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol (2011) 1.81
Sub-lingual immunotherapy: world allergy organization position paper 2009. World Allergy Organ J (2009) 1.03
Therapeutic effects of fermented red ginseng in allergic rhinitis: a randomized, double-blind, placebo-controlled study. Allergy Asthma Immunol Res (2011) 0.99
Development of cockroach immunotherapy by the Inner-City Asthma Consortium. J Allergy Clin Immunol (2013) 0.92
Vaccines for allergy. Curr Opin Immunol (2012) 0.90
Tolerizing allergic responses in the lung. Mucosal Immunol (2010) 0.88
Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy. Clin Transl Allergy (2012) 0.87
Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure. Allergy (2014) 0.84
Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy. Health Qual Life Outcomes (2014) 0.79
Immunotherapy for allergies and asthma: present and future. Curr Opin Pharmacol (2010) 0.79
Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study. Clin Transl Allergy (2016) 0.79
Health-Related Quality of Life During Routine Treatment with the SQ-Standardised Grass Allergy Immunotherapy Tablet: A Non-Interventional Observational Study. Clin Drug Investig (2016) 0.77
Safety and tolerability of an intra-seasonal initiation of the SQ-standardised grass allergy immunotherapy tablet: a non-interventional observational study investigating the feasibility during routine administration. Clin Drug Investig (2013) 0.77
Treatment of grass pollen allergy: focus on a standardized grass allergen extract - Grazax®. Ther Clin Risk Manag (2008) 0.76
[Allergic rhinitis and its impact on asthma (ARIA update 2008). The Austrian perspective]. Wien Med Wochenschr (2009) 0.76
Specific immunotherapy in grass pollen allergy. Hum Vaccin Immunother (2012) 0.76
Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax(®)) in children. Clinicoecon Outcomes Res (2014) 0.76
Critical appraisal of Timothy grass pollen extract GRAZAX(®) in the management of allergic rhinitis. Drug Des Devel Ther (2015) 0.75
Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis. Clinicoecon Outcomes Res (2012) 0.75
How does the efficacy and safety of Oralair(®) compare to other products on the market? Ther Clin Risk Manag (2016) 0.75
Protocol for a randomised, double-blind, placebo-controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal, cutaneous and immunological outcomes. Clin Transl Allergy (2015) 0.75
Oral and sublingual immunotherapy. Curr Treat Options Allergy (2014) 0.75
Comparative analysis of the oral mucosae from rodents and non-rodents: Application to the nonclinical evaluation of sublingual immunotherapy products. PLoS One (2017) 0.75
Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest (2009) 4.10
Evaluation of impermeable covers for bedding in patients with allergic rhinitis. N Engl J Med (2003) 4.00
Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 3.08
Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol (2004) 2.40
SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol (2012) 2.28
Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol (2013) 2.22
Ethnic variations in UK asthma frequency, morbidity, and health-service use: a systematic review and meta-analysis. Lancet (2005) 2.07
Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol (2003) 2.01
Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol (2006) 2.00
Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Chemother (2005) 1.94
Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol (2003) 1.94
Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 1.87
Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol (2007) 1.85
Is occupational asthma to diisocyanates a non-IgE-mediated disease? J Allergy Clin Immunol (2006) 1.68
Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy (2009) 1.65
Tregs and allergic disease. J Clin Invest (2004) 1.64
Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol (2008) 1.64
MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int J Cancer (2010) 1.62
Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol (2011) 1.62
Prognostic significance of isolated HMB45 or Melan A positive cells in Melanoma sentinel lymph nodes. Am J Surg Pathol (2007) 1.58
Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol (2010) 1.55
Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results. Chest (2011) 1.53
Effect of mattress encasings on atopic dermatitis outcome measures in a double-blind, placebo-controlled study: the Dutch mite avoidance study. J Allergy Clin Immunol (2002) 1.46
Mechanisms of immunotherapy. J Allergy Clin Immunol (2004) 1.45
Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol (2008) 1.43
Comparison of classification systems in melanoma sentinel lymph nodes--an analysis of 697 patients from a single center. Cancer (2010) 1.42
The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol Ges (2010) 1.40
Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol (2008) 1.38
Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol (2013) 1.33
Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol (2005) 1.30
Urticaria and infections. Allergy Asthma Clin Immunol (2009) 1.28
Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol (2008) 1.28
Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol (2007) 1.28
Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol (2010) 1.27
Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol (2004) 1.26
Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 1.26
Different effects of CSA and CSB deficiency on sensitivity to oxidative DNA damage. Mol Cell Biol (2004) 1.17
Regulatory T cells and allergic disease. Inflamm Allergy Drug Targets (2008) 1.15
The CX3C chemokine fractalkine in allergic asthma and rhinitis. J Allergy Clin Immunol (2003) 1.13
Chronic urticaria and infections. Curr Opin Allergy Clin Immunol (2004) 1.13
Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol (2007) 1.12
Objective monitoring of nasal airway inflammation in rhinitis. J Allergy Clin Immunol (2005) 1.12
Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature. Dermatology (2009) 1.12
Investigation of contact allergy to dental metals in 206 patients. Contact Dermatitis (2009) 1.10
Mucosal immunity in asthma and chronic obstructive pulmonary disease: a role for immunoglobulin A? Proc Am Thorac Soc (2004) 1.09
Local allergic rhinitis: concept, pathophysiology, and management. J Allergy Clin Immunol (2012) 1.08
Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy. J Allergy Clin Immunol (2012) 1.08
Atypical cutaneous herpes virus infection associated with fludarabine chemotherapy of lymphoma. Eur J Dermatol (2007) 1.07
Development and validation of a health-related quality-of-life questionnaire in patients with yellow jacket allergy. J Allergy Clin Immunol (2002) 1.06
Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol (2007) 1.06
IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis. Pediatr Allergy Immunol (2012) 1.04
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy (2012) 1.04
Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods (2012) 1.04
The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods (2006) 1.03
Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. Arch Dermatol (2012) 1.03
Sub-lingual immunotherapy: world allergy organization position paper 2009. World Allergy Organ J (2009) 1.03
Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol (2011) 1.02
Local somatic hypermutation and class switch recombination in the nasal mucosa of allergic rhinitis patients. J Immunol (2003) 1.02
Myeloperoxidase as a marker of increasing systemic inflammation in smokers without severe airway symptoms. Respir Med (2006) 1.02
IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol (2005) 1.01
Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology (2002) 1.00
Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma. Int J Cancer (2011) 0.99
Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol (2003) 0.99
CCR4 in human allergen-induced late responses in the skin and lung. Eur J Immunol (2002) 0.99
Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol (2004) 0.98
IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy. Immunol Allergy Clin North Am (2006) 0.97
The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol (2002) 0.97
IL-22 suppresses IFN-γ-mediated lung inflammation in asthmatic patients. J Allergy Clin Immunol (2012) 0.96
Germinal-centre reactions in allergic inflammation. Trends Immunol (2006) 0.95
Helicobacter pylori infection in skin diseases: a critical appraisal. Am J Clin Dermatol (2002) 0.95
Resuscitation fluids. N Engl J Med (2013) 0.94
Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Int J Cancer (2007) 0.93
Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology (2005) 0.93
Allergen immunotherapy and tolerance. Allergol Int (2013) 0.92
Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons. Immunology (2004) 0.91
NHS allergy services in the UK: proposals to improve allergy care. Clin Med (2002) 0.91
microRNA-21 is upregulated in malignant melanoma and influences apoptosis of melanocytic cells. Exp Dermatol (2012) 0.90
One hundred years of allergen immunotherapy: time to ring the changes. J Allergy Clin Immunol (2011) 0.90
Basophil interleukin 4 and interleukin 13 production is suppressed during the early phase of rush immunotherapy. Int Arch Allergy Immunol (2006) 0.90
Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther (2013) 0.90
Biased use of VH5 IgE-positive B cells in the nasal mucosa in allergic rhinitis. J Allergy Clin Immunol (2005) 0.89